About Rafael Holdings Inc
- Industry: Pharmaceuticals
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://rafaelholdings.com
Frequently Asked Questions
What is the 52-week range for RFL?
The 52-week high is $3.96 and the 52-week low is $1.12.
What is the P/E ratio for RFL?
The P/E ratio data is currently unavailable.
What is the dividend yield for RFL?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -38.97%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -3321.73%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.92.
Latest RFL News
Cyclo goes forth with Niemann-Pick drug’s approval bid despite Phase III miss
If Trappsol Cyclo gets the regulatory greenlight, it could become the third drug to secure approval in NPC.
Rafael Holdings: A Coin Flip With A Second Binary Attached - Hold
Rafael Holdings is a binary bet on Trappsol Cyclo, which faces tough competition from two approved oral NPC drugs. See why I rate RFL stock as Hold.
Top movers analysis one hour before the close of the markets on 2026-09-30: top gainers and losers in today's session.
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
Let's take a look at the stocks that are in motion in today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.
Crude Oil Rises Over 1%; Conagra Brands Earnings Top Views
U.S. stocks mixed: Dow fell over 200 points, while Nasdaq and S&P 500 rose; inflation cooled and Q2 GDP was revised higher.
Which stocks are gapping on Wednesday?
In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.
Rafael Holdings Shares Fall 25% After Trappsol Cyclo Phase 3 Trial Misses Primary Endpoint
Rafael Holdings Inc Class B (NYSE:RFL) shares fell 25% in pre-market trading on Wednesday after the company’s Phase 3 TransportNPC trial of Trappsol Cyclo in patients with Niemann-Pick Disease Type C (NPC) failed to meet its primary endpoint. The study enrolled 94 patients and evaluated the change from baseline in the 4-domain NPC Clinical Severity Scale at Week 96.
Rafael Holdings stock tumbles 25% as drug trial misses goal
Investing.com -- Rafael Holdings Inc Class B (NYSE:RFL) shares fell 25% in premarket trading Wednesday after the company's Phase 3 trial of Trappsol Cyclo for Niemann-Pick Disease Type C failed to meet its primary endpoint.
Why Is Rafael Stock Falling Wednesday?
Rafael Holdings (NYSE: RFL) stock tumbles after its Phase 3 TransportNPC study of Trappsol Cyclo misses its primary endpoint.
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 147.1% to $0.18 during Wednesday's regular session. Tenon Medical (NASDAQ:TNON) stock increased by 47.25% to $4.02. The market value of their
Wednesday's pre-market session: top gainers and losers
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.
Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)
Trappsol® Cyclo™ did not achieve statistical significance but demonstrated a directionally favorable treatment effect versus placebo on the primary endpoint of change in the 4-domain NPC Clinical Severity Scale (4DNPCSS) at Week 96 A prespecified analysis in patients receiving background miglustat and/or leucine therapy, representing approximately 83% of the study population, showed a statistically significant effect on the 4DNPCSS Trappsol® Cyclo™ demonstrated a well-tolerated safety and tolera
Rafael Holdings, Inc. (RFL) Discusses Topline Results of Phase III TransportNPC Study of Trappsol Cyclo in Niemann-Pick Disease Type C Transcript
Rafael Holdings, Inc. (RFL) Discusses Topline Results of Phase III TransportNPC Study of Trappsol Cyclo in Niemann-Pick Disease Type C September 30, 2026...
Nasdaq Gains Over 100 Points; Jabil Posts Upbeat Earnings
U.S. stocks rose, led by tech, as Jabil beat Q4 estimates and raised FY2027 guidance; oil and gold also climbed.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 106.0% to $0.15 during Wednesday's pre-market session. Connect Biopharma Hldgs (NASDAQ:CNTB) stock increased by 79.43% to $1.78. The market value of
Rafael Holdings Announced Topline Efficacy And Safety Data From Its Cyclo Therapeutics Subsidiary’s Phase 3 TransportNPC Study Evaluating Trappsol Cyclo In 94 Patients Diagnosed With Niemann-Pick Disease Type C; Trappsol Cyclo Did Not Achieve Statistical Significance
Trappsol® Cyclo™ was well tolerated and demonstrated a directionally favorable treatment effect on the primary endpoint, although the result did not achieve statistical significance. Notably, a prespecified analysis in
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-21 | Polinsky David | -2,027 | $2.025 | $4,105 |
| 2026-07-29 | JONAS HOWARD S | +54,945 | $2.73 | $150,000 |
| 2026-06-21 | Polinsky David | -2,386 | $2.635 | $6,287 |
| 2026-06-13 | JONAS HOWARD S | +142,857 | $1.75 | $250,000 |
| 2026-06-13 | JONAS HOWARD S | -8,786 | $2.33 | $20,471 |
| 2026-03-21 | Polinsky David | -2,318 | $1.275 | $2,955 |
| 2026-03-13 | JONAS HOWARD S | -9,826 | $1.5025 | $14,764 |
| 2026-01-28 | Sieger Markus | +29,528 | $1.27 | $37,501 |
| 2026-01-28 | STEIN MARK N | +39,370 | $1.27 | $50,000 |
| 2026-01-28 | GRAYSON ALAN | +6,562 | $1.27 | $8,334 |
| 2026-01-28 | WEISS MICHAEL J | +39,370 | $1.27 | $50,000 |
| 2026-01-13 | Polinsky David | +50,000 | $1.2485 | $62,425 |
| 2026-01-13 | Polinsky David | -4,865 | $1.2485 | $6,074 |
| 2026-01-13 | JONAS HOWARD S | +75,000 | $1.2485 | $93,638 |
| 2025-12-21 | Polinsky David | -1,961 | $1.285 | $2,520 |
| 2025-12-13 | JONAS HOWARD S | -9,867 | $1.4975 | $14,776 |
| 2025-10-25 | Polinsky David | -4,180 | $1.35 | $5,643 |